Literature DB >> 1487559

Cost effectiveness of once-daily oral antimicrobial therapy.

P Davey1, S Parker.   

Abstract

Once daily dosing of oral antimicrobials achieves significantly better patient compliance than three or four times daily dosing, and limited data suggest that this is associated with greater efficacy. Comparison of once daily and twice daily dosing is less consistent, and most studies show only marginally better compliance with once daily dosing versus twice daily dosing. Detection of urinary antimicrobial activity provides a simple method for checking compliance with oral antimicrobials and deserves wider study. Counts of residual tablets have been shown to overestimate compliance. Intravenous formulations are always more expensive than equivalent oral formulations, and preparation and administration of intravenous drugs adds significant additional costs. Moreover, intravenous regimens are complex, and a number of studies have shown that serious errors occur in both preparation and administration of intravenous drugs. There is increasing evidence that serious infections can be adequately treated with oral drugs, and the excellent bioavailability of quinolones makes them particularly attractive for these indications. Clinicians require a method for checking absorption by patients with severe infection, and the Serum Bactericidal Test may provide a practical method for monitoring a wide variety of drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1487559     DOI: 10.1002/j.1552-4604.1992.tb03873.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  6 in total

1.  Cost-effectiveness opportunities for new antibiotics.

Authors:  A Hillman
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

2.  Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection.

Authors:  S Kaul; B Christofalo; R H Raymond; M B Stewart; C M Macleod
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 3.  Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance.

Authors:  Joseph L Kuti; Blair Capitano; David P Nicolau
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

4.  Hepatobiliary elimination of trovafloxacin and metabolites following single oral doses in healthy volunteers.

Authors:  G Melnik; W H Schwesinger; R Teng; L C Dogolo; J Vincent
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267

5.  Antibiotic Expenditures by Medication, Class, and Healthcare Setting in the United States, 2010-2015.

Authors:  Katie J Suda; Lauri A Hicks; Rebecca M Roberts; Robert J Hunkler; Linda M Matusiak; Glen T Schumock
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 20.999

6.  Azithromycin (zithromax).

Authors:  J M McCarty
Journal:  Infect Dis Obstet Gynecol       Date:  1996
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.